Program Description:
Immune checkpoint inhibitors can often play a role in the management of patients with certain gastroesophageal cancers. Join a leading oncology expert to review extended clinical trial data for an Immuno-Oncology (I-O) regimen used across metastatic gastroesophageal cancers. This is also an opportunity to ask questions to better understand the treatment landscape.
Key Takeaways/Learning Objectives:
• Get up to date on the latest clinical trial data for an I-O regimen in certain metastatic gastroesophageal cancers
• Understand how to incorporate I-O therapy into your treatment plan for patients with metastatic gastroesophageal cancers, regardless of tumor location or PD-L1 expression status.